The RPPA facility hosted in the Department of Medical Biochemistry of the Semmelweis University aims to quantitate the expression of all mitochondrial proteins in healthy and solid tumor samples. We believe that alterations in oncometabolism substantiated by changes in proteins expression 'rewiring' certain metabolic pathways provide an excellent opportunity for cancer-specific therapeutic intervention. Identifying those proteins involved in bioenergetic pathways that are up- or downregulated in order to serve the needs of neoplasia, is crucial for beating cancer.
We accept samples from all over the world, but primarily focus in the Central- and Eastern European region. So far, 11 Institutions of the Hungarian Healthcare System and the Human Tissue Brain Bank have pledged their participation to this project by providing healthy and solid tumor samples. Ethical permission for this project has been obtained (file number: 35302-5/2017/EKU), and is valid until June 30th, 2020.
Our main collaborator is Dr. Leanne De Koning, the Manager of the RPPA platform in Institut Curie in Paris, France, who has been instrumental in setting up our RPPA facility. Furthermore, we plan to collaborate with any group using antibodies directed against mitochondrial proteins in an effort to validate antibodies for RPPA suitability, as well as those groups that can provide large number of samples in lysate format (priority given to human samples).